Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study

Autor: Cristian Tomasetti, Dusan Kotasek, Bert Vogelstein, Craig Underhill, Suzanne Kosmider, Julian Choi, Peter Gibbs, Adrian Fox, Wei Hong, Yuxuan Wang, Hui-Li Wong, Jeanne Tie, Christos S Karapetis, Niall C. Tebbutt, Joy Schaeffer, Benjamin N. J. Thomson, Lu Li, Andrew Haydon, Matthew Burge, Joshua D. Cohen, Jenny Shannon, Janine Ptak, Michael Christie, Kenneth W. Kinzler, Kathryn M. Field, Nicholas Papadopoulos, Rachel Wong
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
Male
Colorectal cancer
Adjuvant Chemotherapy
medicine.medical_treatment
Cancer Treatment
Biochemistry
Metastasis
Circulating Tumor DNA
0302 clinical medicine
Interquartile range
Basic Cancer Research
Prospective Studies
Prospective cohort study
Uncategorized
Aged
80 and over
Pharmaceutics
Liver Neoplasms
General Medicine
Middle Aged
Tumor Resection
Prognosis
Surgical Oncology
Treatment Outcome
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Medicine
Female
Colorectal Neoplasms
Research Article
Hepatic Resection
Clinical Oncology
Adult
Risk
medicine.medical_specialty
Surgical and Invasive Medical Procedures
03 medical and health sciences
Cancer Chemotherapy
Digestive System Procedures
Drug Therapy
Cancer detection and diagnosis
Internal medicine
medicine
Adjuvant therapy
Chemotherapy
Humans
Aged
Medicine and health sciences
Colorectal Cancer
Biology and life sciences
Surgical Resection
business.industry
Cancer
Cancers and Neoplasms
medicine.disease
Minimal residual disease
Diagnostic medicine
030104 developmental biology
Clinical Medicine
Neoplasm Recurrence
Local
business
Biomarkers
Zdroj: PLoS Medicine
PLoS Medicine, Vol 18, Iss 5, p e1003620 (2021)
DOI: 10.26181/60e3d4912bf24
Popis: Background In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker of minimal residual disease, is a powerful prognostic factor in patients with nonmetastatic colorectal cancer (CRC). Serial analysis of ctDNA in patients with resectable CRLM could inform the optimal use of perioperative chemotherapy. Here, we performed a validation study to confirm the prognostic impact of postoperative ctDNA in resectable CRLM observed in a previous discovery study. Methods and findings We prospectively collected plasma samples from patients with resectable CRLM, including presurgical and postsurgical samples, serial samples during any pre- or postoperative chemotherapy, and serial samples in follow-up. Via targeted sequencing of 15 genes commonly mutated in CRC, we identified at least 1 somatic mutation in each patient’s tumor. We then designed a personalized assay to assess 1 mutation in plasma samples using the Safe-SeqS assay. A total of 380 plasma samples from 54 patients recruited from July 2011 to Dec 2014 were included in our analysis. Twenty-three (43%) patients received neoadjuvant chemotherapy, and 42 patients (78%) received adjuvant chemotherapy after surgery. Median follow-up was 51 months (interquartile range, 31 to 60 months). At least 1 somatic mutation was identified in all patients’ tumor tissue. ctDNA was detectable in 46/54 (85%) patients prior to any treatment and 12/49 (24%) patients after surgery. There was a median 40.93-fold (19.10 to 87.73, P < 0.001) decrease in ctDNA mutant allele fraction with neoadjuvant chemotherapy, but ctDNA clearance during neoadjuvant chemotherapy was not associated with a better recurrence-free survival (RFS). Patients with detectable postoperative ctDNA experienced a significantly lower RFS (HR 6.3; 95% CI 2.58 to 15.2; P < 0.001) and overall survival (HR 4.2; 95% CI 1.5 to 11.8; P < 0.001) compared to patients with undetectable ctDNA. For the 11 patients with detectable postoperative ctDNA who had serial ctDNA sampling during adjuvant chemotherapy, ctDNA clearance was observed in 3 patients, 2 of whom remained disease-free. All 8 patients with persistently detectable ctDNA after adjuvant chemotherapy have recurred. End-of-treatment (surgery +/− adjuvant chemotherapy) ctDNA detection was associated with a 5-year RFS of 0% compared to 75.6% for patients with an undetectable end-of-treatment ctDNA (HR 14.9; 95% CI 4.94 to 44.7; P < 0.001). Key limitations of the study include the small sample size and the potential for false-positive findings with multiple hypothesis testing. Conclusions We confirmed the prognostic impact of postsurgery and posttreatment ctDNA in patients with resected CRLM. The potential utility of serial ctDNA analysis during adjuvant chemotherapy as an early marker of treatment efficacy was also demonstrated. Further studies are required to define how to optimally integrate ctDNA analyses into decision-making regarding the use and timing of adjuvant therapy for resectable CRLM. Trial registration ACTRN12612000345886.
Author summary Why was this study done? Recurrence risk remains high in patients who underwent curative-intent surgical resection of colorectal cancer liver metastases (CRLM), with limited additional benefit from pre- or postoperative chemotherapy. There is currently no validated biomarker of recurrence for resected CRLM that could help guide the use of chemotherapy for the individual patient. Circulating tumor DNA (ctDNA), representing DNA shed from tumor cells into the circulation, is a versatile blood-based biomarker that can provide real-time assessment of cancer burden. It has been shown in a previous small study of 18 patients that ctDNA detection after surgery for CRLM is highly predictive of eventual cancer relapse. What did the researchers do and find? We performed a larger study involving 54 patients with resectable CRLM to confirm the ability of postoperative ctDNA to detect microscopic residual disease and predict relapse. We also analysed serial ctDNA during and after chemotherapy. ctDNA was detected in 24% of patients immediately after surgery, and these patients had a very high recurrence risk of 83% compared to only 31% in those with undetectable ctDNA after surgery. All patients with detectable postoperative ctDNA who failed to clear their ctDNA following adjuvant chemotherapy experienced recurrence, while 67% of patients whose ctDNA became undetectable after chemotherapy remained disease-free. What do these findings mean? ctDNA detection after surgery or after completion of adjuvant chemotherapy is associated with a very high risk of recurrence and death in patients with resectable CRLM; ctDNA dynamics before and after adjuvant chemotherapy reflected adjuvant treatment efficacy. Future studies should aim to assess how best to incorporate ctDNA testing into clinical practice to guide adjuvant treatment decision.
Databáze: OpenAIRE
Externí odkaz: